Latest Taxation News

Adelong Gold Limited has received a $1.17 million tax indemnity claim linked to alleged fraudulent GST reporting at Challenger Mines, which it plans to dispute. The claim stems from activities predating the current management team.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

FAR Limited has agreed on a provisional US$23.7 million contingent payment from Woodside Energy tied to the Sangomar Project, prompting a proposed capital return of A$32.3 million to shareholders.

The Brazilian government has imposed a 12% tax on crude oil exports effective immediately, a move framed as windfall profit sharing amid high oil prices. Karoon Energy, with significant Brazilian operations, faces new cost pressures as the tax awaits potential ratification by Congress.

Janus Electric has locked in a $2.75 million R&D finance facility, strengthening its cash position to push forward with its zero-emission transport innovations. This strategic funding avoids shareholder dilution while supporting ongoing technology development.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Betashares Capital Ltd has announced the final distribution amounts for February 2026 across a broad range of its ETFs listed on the ASX AQUA market, alongside details on the Distribution Reinvestment Plan.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

US Masters Residential Property Group reported a $57.3 million net loss for 2025 amid a strategic shift to wind down operations by selling its entire US residential property portfolio by the end of 2026. The Group surpassed its aggressive 2025 sales target, setting the stage for capital returns to security holders.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.